On July 30, Dongyang Pharmaceutical announced that its self-developed Tokugu insulin injection was officially approved for marketing by the State Drug Administration, covering the two specifications of refills and pre-filled injection pens. With the approval of this product, Dongyangyang Pharmaceutical's insulin products in the Chinese market have increased to 6, forming a full range of product matrices covering the second to fourth generation and covering the three major clinical scenarios of basic, meal time, and premixing. In addition, the company's Degumendong double insulin injection is already in the marketing registration review stage, and the innovative drug HEC-151, an ultra-long-lasting insulin weekly formulation, has entered phase I clinical trials.

On July 30, Dongyang Pharmaceutical announced that its self-developed Tokugu insulin injection was officially approved for marketing by the State Drug Administration, covering the two specifications of refills and pre-filled injection pens. With the approval of this product, Dongyangyang Pharmaceutical's insulin products in the Chinese market have increased to 6, forming a full range of product matrices covering the second to fourth generation and covering the three major clinical scenarios of basic, meal time, and premixing. In addition, the company's Degumendong double insulin injection is already in the marketing registration review stage, and the innovative drug HEC-151, an ultra-long-lasting insulin weekly formulation, has entered phase I clinical trials.